[Effect of molsidomine on fibrinolytic activity: a double-blind, randomized study].
The influence of molsidomine on endogenous fibrinolytic activity was studied in a double-blind, randomized, placebo-controlled trial involving 12 male healthy volunteers. When measured 3 h after oral intake of molsidomine (16 mg, slow-release formulation) the activity of tissue plasminogen activator (t-PA) in plasma was significantly increased from 1.1 +/- 0.1 to 1.6 +/- 0.1 IU/ml. In contrast, the activity of plasminogen activator inhibitor (PAI-I) decreased from 17 +/- 2 to 12 +/- 1 AU/ml. The ratio of t-PA/PAI-I (x 100), calculated as index for the endogenous fibrinolytic activity increased significantly from 8.1 +/- 1.1 to 14.5 +/- 1.6. The ratio was unaltered after intake of placebo. Additionally, collagen-induced platelet aggregation was significantly inhibited following intake of molsidomine. The results demonstrate a significant increase in endogenous fibrinolytic activity after oral intake of molsidomine. These effects may be of therapeutic value in patients with coronary heart disease and unstable angina.
Darius
H
H
II. Medizinische Klinik und Poliklinik, Johannes Gutenberg-Universität, Mainz.
Grodzinska
L
L
Hafner
G
G
Meyer
J
J
D000284:Administration, Oral; D000328:Adult; D004311:Double-Blind Method; D005342:Fibrinolysis / Q000187:drug effects*; D006801:Humans; D008297:Male; D008981:Molsidomine / Q000494:pharmacology*; D015849:Plasminogen Inactivators / Q000097:blood; D010974:Platelet Aggregation / Q000187:drug effects; D010975:Platelet Aggregation Inhibitors / Q000494:pharmacology; D010959:Tissue Plasminogen Activator / Q000378:metabolism
D015849:Plasminogen Inactivators; D010975:Platelet Aggregation Inhibitors; D008981:Molsidomine; D010959:Tissue Plasminogen Activator
Wirkung von Molsidomin auf die fibrinolytische Aktivität: eine doppelblinde, randomisierte Studie.